Detalles de la búsqueda
1.
Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
Cancer Causes Control
; 35(3): 509-521, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878135
2.
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Prostate
; 83(14): 1351-1357, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37424145
3.
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
BMC Cancer
; 23(1): 781, 2023 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608258
4.
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Br J Cancer
; 126(3): 430-439, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35046520
5.
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).
Mol Carcinog
; 61(9): 851-864, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35726553
6.
Cancer and cardiovascular-related perceived risk in a diverse cancer center catchment area.
Cancer Causes Control
; 33(5): 759-768, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274199
7.
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted ß-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Prostate
; 81(5): 279-285, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465252
8.
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Genes Chromosomes Cancer
; 59(4): 225-239, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705765
9.
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
Oncologist
; 25(6): 477-e895, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31999003
10.
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Invest New Drugs
; 38(5): 1383-1389, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898184
11.
All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Eur J Haematol
; 104(3): 236-250, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31811682
12.
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Cancer
; 125(15): 2561-2569, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012963
13.
Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Phys Biol
; 16(3): 036003, 2019 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30763921
14.
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.
J Natl Compr Canc Netw
; 17(3): 194-200, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30865916
15.
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
Cancer
; 124(5): 1008-1015, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266381
16.
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Cancer
; 120(5): 692-701, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24249435
17.
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
J Clin Oncol
; 42(7): 842-851, 2024 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37922438
18.
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Clin Cancer Res
; 30(6): 1152-1159, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236581
19.
Negative regulation of NEP expression by hypoxia.
Prostate
; 73(7): 706-14, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23138928
20.
Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy.
Eur Urol Open Sci
; 57: 1-7, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38020528